Skip to main content

Advertisement

SpringerLink
Log in

Treatment of functional dyspepsia

  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

Functional dyspepsia (FD) is a common reason a patient presents with upper gastrointestinal symptoms for medical care. Although treatment of FD remains expensive, the agents are rarely used in a systematic manner; the majority of treatments are empirical and the results short lived once therapy is ceased. This is partly due to the lack of consistent pathophysiologic markers in FD, so therapy is symptom driven. This review appraises the best evidence on available interventions. A structured scheme for deciding on appropriate therapies is to consider the possible putative pathophysiologic mechanisms. Eradicating Helicobacter pylori, if present, is a first-line strategy. In patients who have symptoms suggesting excessive gastric acid secretion, particularly epigastric pain, antisecretory agents are recommended. Prokinetics may confer benefits on symptoms suggestive of upper gastrointestinal dysmotility, like fullness or early satiety. However, their use is limited due to availability issues. The expanding field of psychologic therapies provides a promising avenue of treatment. Complementary medicines are now widely use and their benefits have been suggested in recent controlled trials. Emerging treatments include cholecystokinin 1 blockers, opioid receptor agonists, and serotonergic agents, although their application in FD is in the preliminary stages.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Locke GR, 3rd: The epidemiology of functional gastrointestinal disorders in North America. Gastroenterol Clin North Am 1996, 25: 1–19.

    Article  PubMed  Google Scholar 

  2. Nyren O, Lindberg G, Lindstrom E, et al.: Economic costs of functional dyspepsia. Pharmacoeconomics 1992, 1: 312–324.

    Article  PubMed  CAS  Google Scholar 

  3. Moayyedi P, Mason J: Clinical and economic consequences of dyspepsia in the community. Gut 2002, 50(Suppl 4):iv10-iv12.

    Article  PubMed  Google Scholar 

  4. Stanghellini V, Tosetti C, Paternic A, et al.: Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology 1996, 110: 1036–1042.

    Article  PubMed  CAS  Google Scholar 

  5. Tack J, Caenepeel P, Fischler B, et al.: Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia. Gastroenterology 2001, 121: 526–535.

    Article  PubMed  CAS  Google Scholar 

  6. Samsom M, Verhagen MA, van Berge Henegouwen GP, et al.: Abnormal clearance of exogenous acid and increased acid sensitivity of the proximal duodenum in dyspeptic patients. Gastroenterology 1999, 116: 515–520.

    Article  PubMed  CAS  Google Scholar 

  7. Holtmann G, Siffert W, Haag S, et al.: G-protein beta 3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia. Gastroenterology 2004, 126: 971–979.

    Article  PubMed  CAS  Google Scholar 

  8. Talley NJ, Silverstein MD, Agreus L, et al.: AGA technical review: evaluation of dyspepsia. American Gastroenterological Association. Gastroenterology 1998, 114: 582–595.

    Article  PubMed  CAS  Google Scholar 

  9. Talley NJ, Quan C: Review article: Helicobacter pylori and nonulcer dyspepsia. Aliment Pharmacol Ther 2002, 16(Suppl 1):58–65.

    Article  PubMed  Google Scholar 

  10. MoayyediP, Soo S, Deeks J, et al.: Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2005, 1: CD002096. The most comprehensive systematic review on this controversial subject. Updated regularly.

    PubMed  Google Scholar 

  11. Chiba N, Van Zanten SJ, Sinclair P, et al.: Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial.[see comment]. BMJ 2002, 324: 1012–1016.

    Article  PubMed  CAS  Google Scholar 

  12. Farkkila M, Sarna S, Valtonen V, et al.: Does the ‘test-and-treat’ strategy work in primary health care for management of uninvestigated dyspepsia? A prospective two-year follow-up study of 1552 patients. Scandinavian Journal of Gastroenterology 2004, 39: 327–335.

    Article  PubMed  CAS  Google Scholar 

  13. Moayyedi P, Delaney BC, Vakil N, et al.: The efficacy of proton pump inhibitors in nonulcer dyspepsia: A systematic review and economic analysis. Gastroenterology 2004, 127: 1329–1337.

    Article  PubMed  Google Scholar 

  14. Moayyedi P, Soo S, Deeks J, et al.: Systematic review: Antacids, H2-receptor antagonists, prokinetics, bismuth and sucralfate therapy for non-ulcer dyspepsia. Aliment Pharmacol Ther 2003, 17: 1215–1227. Useful overview of the merits of current pharmacological treatments for dyspepsia. Treatments are evaluated in comparison to each other as well as placebo.

    Article  PubMed  CAS  Google Scholar 

  15. Tatsuta M, Iishi H, Nakaizumi A, et al.: Effect of treatment with cisapride alone or in combination with domperidone on gastric emptying and gastrointestinal symptoms in dyspeptic patients. Aliment Pharmacol Ther 1992, 6: 221–228.

    Article  PubMed  CAS  Google Scholar 

  16. Corinaldesi R, Stanghellini V, Raiti C, et al.: Effect of chronic administration of cisapride on gastric emptying of a solid meal and on dyspeptic symptoms in patients with idiopathic gastroparesis. Gut 1987, 28: 300–305.

    PubMed  CAS  Google Scholar 

  17. Kellow JE, Cowan H, Shuter B, et al.: Efficacy of cisapride therapy in functional dyspepsia. Aliment Pharmacol Ther 1995, 9: 153–160.

    Article  PubMed  CAS  Google Scholar 

  18. TackJ, Bisschops R, Sarnelli G: Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004, 127(4):1239–1255. Excellent overview of the current theories behind the mechanisms of functional dyspepisa.

    Article  PubMed  Google Scholar 

  19. Gotthard R, Bodemar G, Brodin U, et al.: Treatment with cimetidine, antacid, or placebo in patients with dyspepsia of unknown origin. Scand J Gastroenterol 1988, 23: 7–18.

    PubMed  CAS  Google Scholar 

  20. Nyren O, Adami HO, Bates S, et al.: Absence of therapeutic benefit from antacids or cimetidine in non-ulcer dyspepsia. N Engl J Med 1986, 314: 339–343.

    Article  PubMed  CAS  Google Scholar 

  21. Moayyedi P, Soo S, Deeks J, et al.: Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2004:CD001960.

  22. Haug TT, Svebak S, Wilhelmsen I, et al.: Psychological factors and somatic symptoms in functional dyspepsia. A comparison with duodenal ulcer and healthy controls. J Psychosom Res 1994, 38: 281–291.

    Article  PubMed  CAS  Google Scholar 

  23. Talley NJ, Fung LH, Gilligan IJ, et al.: Association of anxiety, neuroticism, and depression with dyspepsia of unknown cause. A case-control study. Gastroenterology 1986, 90: 886–892.

    PubMed  CAS  Google Scholar 

  24. Haug TT, Svebak S, Hausken T, et al.: Low vagal activity as mediating mechanism for the relationship between personality factors and gastric symptoms in functional dyspepsia. Psychosom Med 1994, 56: 181–186.

    PubMed  CAS  Google Scholar 

  25. Lorena SL, Tinois E, Brunetto SQ, et al.: Gastric emptying and intragastric distribution of a solid meal in functional dyspepsia: influence of gender and anxiety. J Clin Gastroenterol 2004, 38: 230–236.

    Article  PubMed  Google Scholar 

  26. Camilleri M, Malagelada JR, Kao PC, et al.: Gastric and autonomic responses to stress in functional dyspepsia. Dig Dis Sci 1986, 31: 1169–1177.

    Article  PubMed  CAS  Google Scholar 

  27. Soo S, Moayyedi P, Deeks J, et al.: Psychological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2004:CD002301.

  28. Haug TT, Wilhelmsen I, Svebak S, et al.: Psychotherapy in functional dyspepsia. J Psychosom Res 1994, 38: 735–744.

    Article  PubMed  CAS  Google Scholar 

  29. Hamilton J, Guthrie E, Creed F, et al.: A randomized controlled trial of psychotherapy in patients with chronic functional dyspepsia. Gastroenterology 2000, 119: 661–669.

    Article  PubMed  CAS  Google Scholar 

  30. Calvert EL, Houghton LA, Cooper P, et al.: Long-term improvement in functional dyspepsia using hypnotherapy. Gastroenterology 2002, 123: 1778–1785.

    Article  PubMed  Google Scholar 

  31. Bates S, Sjoden PO, Nyren O: Behavioral treatment of non-ulcer dyspepsia. Scand J Behav Ther 1988, 17: 155–165.

    Google Scholar 

  32. Jackson JL, O’Malley PG, Tomkins G, et al.: Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000, 108: 65–72.

    Article  PubMed  CAS  Google Scholar 

  33. Loldrup D, Langemark M, Hansen HJ, et al.: Clomipramine and mianserin in chronic idiopathic pain syndrome. A placebo controlled study. Psychopharmacology (Berl) 1989, 99: 1–7.

    Article  CAS  Google Scholar 

  34. Mertz H, Fass R, Kodner A, et al.: Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol 1998, 93(2):160–165.

    Article  PubMed  CAS  Google Scholar 

  35. Tack J, Broekaert D, Coulie B, et al.: Influence of the selective serotonin re-uptake inhibitor, paroxetine, on gastric sensorimotor function in humans. Aliment Pharmacol Ther 2003, 17: 603–608.

    Article  PubMed  CAS  Google Scholar 

  36. Tindle HA, Davis RB, Phillips RS, et al.: Trends in use of complementary and alternative medicine by US adults: 1997–2002. Altern Ther Health Med 2005, 11: 42–49.

    PubMed  Google Scholar 

  37. Holtmann G, Adam B, Haag S, et al.: Efficacy of artichoke leaf extract in the treatment of patients with functional dyspepsia: a six-week placebocontrolled, double-blind, multicentre trial. Aliment Pharmacol Ther 2003, 18: 1099–1105.

    Article  PubMed  CAS  Google Scholar 

  38. Thompson Coon J, Ernst E: Herbal medicinal products for non-ulcer dyspepsia. Aliment Pharmacol Ther 2002, 16: 1689–1699.

    Article  PubMed  CAS  Google Scholar 

  39. Melzer J, Rosch W, Reichling J, et al.: Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). Aliment Pharmacol Ther 2004, 20: 1279–1287.

    Article  PubMed  CAS  Google Scholar 

  40. Tack J, Piessevaux H, Coulie B, et al.: Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998, 115: 1346–1352.

    Article  PubMed  CAS  Google Scholar 

  41. Mertz H, Fullerton S, Naliboff B, et al.: Symptoms and visceral perception in severe functional and organic dyspepsia. Gut 1998, 42: 814–822.

    Article  PubMed  CAS  Google Scholar 

  42. Tack J, Coulie B, Wilmer A, et al.: Influence of sumatriptan on gastric fundus tone and on the perception of gastric distension in man. Gut 2000, 46: 468–473.

    Article  PubMed  CAS  Google Scholar 

  43. Tack J, Caenepeel P, Corsetti M, et al.: Role of tension receptors in dyspeptic patients with hypersensitivity to gastric distention. Gastroenterology 2004, 127: 1058–1066.

    Article  PubMed  Google Scholar 

  44. Camilleri M, Mayer EA, Drossman DA, et al.: Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999, 13: 1149–1159.

    Article  PubMed  CAS  Google Scholar 

  45. Talley NJ, Van Zanten SV, Saez LR, et al.: A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia. Aliment Pharmacol Ther 2001, 15: 525–537.

    Article  PubMed  CAS  Google Scholar 

  46. Delvaux M, Louvel D, Lagier E, et al.: The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology 1999, 116: 38–45.

    Article  PubMed  CAS  Google Scholar 

  47. Read NW, Abitbol JL, Bardhan KD, et al.: Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia. Gut 1997, 41: 664–668.

    Article  PubMed  CAS  Google Scholar 

  48. Fraitag B, Homerin M, Hecketsweiler P: Double-blind dose-response multicenter comparison of fedotozine and placebo in treatment of nonulcer dyspepsia. Dig Dis Sci 1994, 39: 1072–1077.

    Article  PubMed  CAS  Google Scholar 

  49. Delgado-Aros S, Chial HJ, Cremonini F, et al.: Effects of asimadoline, a kappa-opioid agonist, on satiation and postprandial symptoms in health. Aliment Pharmacol Ther 2003, 18: 507–514.

    Article  PubMed  CAS  Google Scholar 

  50. Mansi C, Borro P, Giacomini M, et al.: Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis. Aliment Pharmacol Ther 2000, 14: 561–569.

    Article  PubMed  CAS  Google Scholar 

  51. Distrutti E, Fiorucci S, Hauer SK, et al.: Effect of acute and chronic levosulpiride administration on gastric tone and perception in functional dyspepsia. Aliment Pharmacol Ther 2002, 16: 613–622.

    Article  PubMed  CAS  Google Scholar 

  52. Mearin F, Rodrigo L, Perez-Mota A, et al.: Levosulpiride and cisapride in the treatment of dysmotility-like functional dyspepsia: a randomized, double-masked trial. Clin Gastroenterol Hepatol 2004, 2: 301–308.

    Article  PubMed  CAS  Google Scholar 

  53. Tsubouchi T, Saito T, Mizutani F, et al.: Stimulatory action of itopride hydrochloride on colonic motor activity in vitro and in vivo. J Pharmacol Exp Ther 2003, 306: 787–793. Epub 2003 Apr 30.

    Article  PubMed  CAS  Google Scholar 

  54. Holtmann G, Schnittker J, Boos G, et al.: A randomized, double-blind, placebo-controlled dose finding study of Itopride for the treatment of patients with funcitonal dyspepsia. Gastroenterology 2004, 126: A-100.

    Article  CAS  Google Scholar 

  55. Feinle C, Grundy D, Otto B, et al.: Relationship between increasing duodenal lipid doses, gastric perception, and plasma hormone levels in humans. Am J Physiol Regul Integr Comp Physiol 2000, 278: R1217-R1223.

    PubMed  CAS  Google Scholar 

  56. Moran TH, Kinzig KP: Gastrointestinal satiety signals II. Cholecystokinin. Am J Physiol Gastrointest Liver Physiol 2004, 286: G183-G188.

    Article  PubMed  CAS  Google Scholar 

  57. Feinle C, Meier O, Otto B, et al.: Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia. Gut 2001, 48: 347–355.

    Article  PubMed  CAS  Google Scholar 

  58. Varga G: Dexloxiglumide Rotta Research Lab. Curr Opin Investig Drugs 2002, 3: 621–626.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mayo Clinic Rochester, 200 First Street SW, 55905, Rochester, MN, USA

    Smita L. S. Halder MRCP, MRes & Nicholas J. Talley MD, PhD

Authors
  1. Smita L. S. Halder MRCP, MRes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicholas J. Talley MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Halder, S.L.S., Talley, N.J. Treatment of functional dyspepsia. Curr Treat Options Gastro 8, 325–336 (2005). https://doi.org/10.1007/s11938-005-0026-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-005-0026-8

Keywords

Search

Navigation